Selecta Biosciences Inc. (SELB)
Selecta Biosciences Statistics
Share Statistics
Selecta Biosciences has 153.43M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 153.43M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 94M |
| Failed to Deliver (FTD) Shares | 8 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 7.98M, so 5.2% of the outstanding shares have been sold short.
| Short Interest | 7.98M |
| Short % of Shares Out | 5.2% |
| Short % of Float | 7.8% |
| Short Ratio (days to cover) | 17.33 |
Valuation Ratios
The PE ratio is -471.1 and the forward PE ratio is null. Selecta Biosciences's PEG ratio is 4.68.
| PE Ratio | -471.1 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -235.14 |
| P/FCF Ratio | -2015 |
| PEG Ratio | 4.68 |
Enterprise Valuation
Selecta Biosciences has an Enterprise Value (EV) of 103.44B.
| EV / Sales | 0 |
| EV / EBITDA | -1196.98 |
| EV / EBIT | -2021.83 |
| EV / FCF | -2013.72 |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of -0.02.
| Current Ratio | 1.33 |
| Quick Ratio | 1.33 |
| Debt / Equity | -0.02 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.21 |
| Interest Coverage | 30.5 |
Financial Efficiency
Return on Equity is 49.91% and Return on Invested Capital is 21.74%.
| Return on Equity | 49.91% |
| Return on Assets | -72.02% |
| Return on Invested Capital | 21.74% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.43M |
| Employee Count | 64 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 19M |
| Effective Tax Rate | -7.96% |
Stock Price Statistics
The stock price has increased by 31.87% in the last 52 weeks. The beta is 0.83, so Selecta Biosciences's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | 31.87% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 37.34 |
| Average Volume (20 Days) | 634.42K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -86.42M |
| Net Income | -219.71M |
| EBITDA | -86.42M |
| EBIT | -241.54M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 76.91M in cash and 10.96M in debt, giving a net cash position of 65.96M.
| Cash & Cash Equivalents | 76.91M |
| Total Debt | 10.96M |
| Net Cash | 65.96M |
| Retained Earnings | -614.65M |
| Total Assets | 305.05M |
| Working Capital | 22.52M |
Cash Flow
In the last 12 months, operating cash flow was -51.16M and capital expenditures -206K, giving a free cash flow of -51.37M.
| Operating Cash Flow | -51.16M |
| Capital Expenditures | -206K |
| Free Cash Flow | -51.37M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SELB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.21% |
| FCF Yield | -0.05% |
Analyst Forecast
Currently there are no analyst rating for SELB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -3.07 |
| Piotroski F-Score | 3 |